TILT Biotherapeutics
Latest round
- Series B
Last raised
- May 2025
Total raised
- $26M
Investors
- 4
About TILT Biotherapeutics
TILT Biotherapeutics Oy develops advanced immunotherapies for cancer treatment. Founded in 2013 in Helsinki, Finland, the company has engaged in a total of 9 deals.TILT Biotherapeutics (Tiltbio) specializes in the development of advanced immunotherapies targeting solid tumors, with a primary focus on platinum-resistant ovarian cancer. Their flagship product, TILT-123, is a cytokine-armed oncolytic adenovirus designed for intravenous delivery. This innovative therapy uses modified viruses to infect and stimulate cancer cells, enhancing the immune system's recognition and attack on tumors. TILT-123 is currently undergoing Phase I/II clinical trials in both Europe and the United States, administered as a standalone treatment and in combination with other immunotherapies, such as immune checkpoint inhibitors and tumor-infiltrating lymphocyte therapy. The company targets a patient population with limited treatment options, specifically those who have not responded effectively to conventional treatments like surgery and chemotherapy.TILT Biotherapeutics generates revenue through partnerships and collaborations with pharmaceutical companies, focusing on the development and clinical evaluation of their investigational therapies. These collaborations involve shared costs and revenue from the commercialization of their therapies, providing a structured transaction framework based on mutual investment in clinical trials and research initiatives. The company has plans for expanding its clinical trials geographically, focusing on both European and United States markets, aiming to establish a broader footprint in the immunotherapy field as they progress through clinical development.
Who invested in TILT Biotherapeutics
4 investors across 1 round
See all investors in TILT Biotherapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series B
May 13, 2025
Amount
$26M
Investors
Questions about TILT Biotherapeutics
Who invested in TILT Biotherapeutics?
TILT Biotherapeutics has 4 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TILT Biotherapeutics raised?
TILT Biotherapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did TILT Biotherapeutics last raise money?
TILT Biotherapeutics's most recent round on record is a Series B, in May 2025.
What does TILT Biotherapeutics do?
TILT Biotherapeutics Oy develops advanced immunotherapies for cancer treatment.
Where is TILT Biotherapeutics headquartered?
TILT Biotherapeutics is headquartered in Helsinki, Finland.
Which VCs invest in companies like TILT Biotherapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Generation Investment Management back biotechnology companies at TILT Biotherapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like TILT Biotherapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.